(Q36106955)

12 August 2017

1 reference

title

Venlafaxine in the treatment of anxiety disorders (English)

1 reference

12 August 2017

Martin Katzman

1

1 reference

12 August 2017

publication date

1 May 2004

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

371-381

1 reference

Paroxetine efficacy in the treatment of generalized anxiety disorder

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Effects of duloxetine on painful physical symptoms associated with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Tricyclic antidepressant use in diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Management strategies for the treatment of neuropathic pain in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French Pharmacovigilance database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Severe headache with venlafaxine withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Shock‐Like Sensations During Venlafaxine Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Antidepressant discontinuation syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Effect of venlafaxine on imipramine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

A case of serotonin syndrome caused by venlafaxine and lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Pharmacokinetics of haloperidol: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.3.371

21 January 2018

Identifiers

DOI

10.1586/14737175.4.3.371

1 reference

12 August 2017

1 reference